| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| John T Walku. Antidepressant Efficacy for Depression in Children and Adolescents: Industry- and NIMH-Funded Studies. The American journal of psychiatry. vol 174. issue 5. 2017-06-19. PMID:28253735. |
the nimh-funded trials, taken together with the demonstrated efficacy of the serotonin reuptake inhibitors for childhood-onset obsessive-compulsive disorder and the anxiety disorders, suggest a broad and important role for antidepressant medications in pediatric internalizing conditions. |
2017-06-19 |
2023-08-13 |
Not clear |
| Yasmin Issari, Ewgeni Jakubovski, Christine A Bartley, Christopher Pittenger, Michael H Bloc. Early onset of response with selective serotonin reuptake inhibitors in obsessive-compulsive disorder: a meta-analysis. The Journal of clinical psychiatry. vol 77. issue 5. 2017-06-07. PMID:27249090. |
early onset of response with selective serotonin reuptake inhibitors in obsessive-compulsive disorder: a meta-analysis. |
2017-06-07 |
2023-08-13 |
Not clear |
| Yasmin Issari, Ewgeni Jakubovski, Christine A Bartley, Christopher Pittenger, Michael H Bloc. Early onset of response with selective serotonin reuptake inhibitors in obsessive-compulsive disorder: a meta-analysis. The Journal of clinical psychiatry. vol 77. issue 5. 2017-06-07. PMID:27249090. |
selective serotonin reuptake inhibitors (ssris) are recommended as the first-line pharmacologic treatment for obsessive-compulsive disorder (ocd). |
2017-06-07 |
2023-08-13 |
Not clear |
| Raşit Tükel, Elif Alkaş, Hakan Gürvit, Banu Aslantaş Ertekin, Erhan Ertekin, Bengi Baran, Şükriye Akça Kalem, Güher Saruhan Direskenel. Serotonin transporter promoter polymorphism is associated with executive function impairments in patients with obsessive compulsive disorder. The Clinical neuropsychologist. vol 30. issue 4. 2017-05-31. PMID:26986829. |
serotonin transporter promoter polymorphism is associated with executive function impairments in patients with obsessive compulsive disorder. |
2017-05-31 |
2023-08-13 |
Not clear |
| Thiago Sampaio, Cristiane Lima, Fabio Corregiari, Marcio Berni. The putative catalytic role of higher serotonin bioavailability in the clinical response to exposure and response prevention in obsessive-compulsive disorder. Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999). vol 38. issue 4. 2017-05-02. PMID:27798711. |
the putative catalytic role of higher serotonin bioavailability in the clinical response to exposure and response prevention in obsessive-compulsive disorder. |
2017-05-02 |
2023-08-13 |
Not clear |
| Thiago Sampaio, Cristiane Lima, Fabio Corregiari, Marcio Berni. The putative catalytic role of higher serotonin bioavailability in the clinical response to exposure and response prevention in obsessive-compulsive disorder. Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999). vol 38. issue 4. 2017-05-02. PMID:27798711. |
the objective of this study was to investigate whether pre-treatment platelet rich plasma (prp) 5-ht concentration is associated with latency of treatment response and final response to an erp protocol for obsessive-compulsive disorder (ocd). |
2017-05-02 |
2023-08-13 |
Not clear |
| Tracy P Bhikram, Norman A S Farb, Lakshmi N Ravindran, Yousef G Papadopoulos, David K Conn, Bruce G Pollock, Arun V Ravindra. The Effect of Intravenous Citalopram on the Neural Substrates of Obsessive-Compulsive Disorder. The Journal of neuropsychiatry and clinical neurosciences. vol 28. issue 3. 2017-04-10. PMID:27019066. |
this study investigated the effect of an intravenous serotonin reuptake inhibitor on the neural substrates of obsessive-compulsive disorder (ocd), as intravenous agents may be more effective in treating ocd than conventional oral pharmacotherapy. |
2017-04-10 |
2023-08-13 |
human |
| Umberto Albert, Filippo Bogett. [Treatment of obsessive-compulsive disorder: drugs, psychotherapy or combined treatments?]. Rivista di psichiatria. vol 50. issue 4. 2017-03-21. PMID:26418594. |
serotonin reuptake inhibitors (sris) and cognitive-behavioral psychotherapy (cbt) are first-line treatments for obsessive-compulsive disorder (ocd). |
2017-03-21 |
2023-08-13 |
human |
| Marie Spies, Gitte M Knudsen, Rupert Lanzenberger, Siegfried Kaspe. The serotonin transporter in psychiatric disorders: insights from PET imaging. The lancet. Psychiatry. vol 2. issue 8. 2017-01-30. PMID:26249305. |
additionally, this review discusses pet studies investigating the serotonin transporter in anxiety, obsessive-compulsive disorder, and eating disorders. |
2017-01-30 |
2023-08-13 |
Not clear |
| Matthijs G P Feenstra, André Klompmakers, Martijn Figee, Sjoerd Fluitman, Nienke Vulink, Herman G M Westenberg, Damiaan Deny. Prazosin addition to fluvoxamine: A preclinical study and open clinical trial in OCD. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 26. issue 2. 2016-12-13. PMID:26712326. |
the clinical trial "prazosin in combination with a serotonin reuptake inhibitor for patients with obsessive compulsive disorder: an open label study" was registered at 24/05/2011 under trial number isrctn61562706: http://www.controlled-trials.com/isrctn61562706. |
2016-12-13 |
2023-08-13 |
rat |
| Yasuhide Nagoshi, Toshiyuki Tominaga, Kenji Fuku. Blonanserin Augmentation for Treatment-Resistant Somatic Symptom Disorder: A Case Series. Clinical neuropharmacology. vol 39. issue 2. 2016-12-13. PMID:26818044. |
the augmentation of selective serotonin reuptake inhibitors with antipsychotics that have a high dopamine-receptor-d2 affinity may be effective in treatment-resistant obsessive-compulsive disorder and somatic symptom disorder, which is similar to illness anxiety disorder. |
2016-12-13 |
2023-08-13 |
Not clear |
| Soumeyya Halayem, Sami Othman, Hajer Ben Youssef, Ahlem Belhaj, Anissa Bouasker, Rym Ghachem, Karim Tabbane, Asma Boude. [The Usefulness of Clonazepam as an Augmentative Treatment in a Case of Severe Childhood Onset Obsessive-Compulsive Disorder]. Turk psikiyatri dergisi = Turkish journal of psychiatry. vol 26. issue 4. 2016-10-28. PMID:26731026. |
we report on the case of a young teenage girl with an extremely severe form of obsessive-compulsive disorder (score of 32 on the children's yale-brown obsessive compulsive scale), who, after a mild improvement with a combination of serotonin recapture inhibitors and second generation antipsychotics at high doses, has responded to clonazepam (3mg/day) augmentation of sertraline (200mg/day) and olanzapine (15mg/day). |
2016-10-28 |
2023-08-13 |
Not clear |
| H Qin, J F Samuels, Y Wang, Y Zhu, M A Grados, M A Riddle, B D Greenberg, J A Knowles, A J Fyer, J T McCracken, D L Murphy, S A Rasmussen, B A Cullen, J Piacentini, D Geller, S E Stewart, D Pauls, O J Bienvenu, F S Goes, B Maher, A E Pulver, D Valle, C Lange, M Mattheisen, N C McLaughlin, K-Y Liang, E L Nurmi, K D Askland, G Nestadt, Y Y Shugar. Whole-genome association analysis of treatment response in obsessive-compulsive disorder. Molecular psychiatry. vol 21. issue 2. 2016-10-19. PMID:25824302. |
up to 30% of patients with obsessive-compulsive disorder (ocd) exhibit an inadequate response to serotonin reuptake inhibitors (sris). |
2016-10-19 |
2023-08-13 |
Not clear |
| Antonio Bruno, Gianluca Pandolfo, Clemente Cedro, Giuseppa Gallo, Mariangela De Felice, Rocco A Zoccali, Maria Rosaria A Muscatell. Effect of Ziprasidone Augmentation of Serotonin Reuptake Inhibitors in Treatment-Resistant Obsessive-Compulsive Disorder: A 12-Week, Open-Label Uncontrolled Preliminary Study. Clinical neuropharmacology. vol 39. issue 1. 2016-10-11. PMID:26757309. |
effect of ziprasidone augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a 12-week, open-label uncontrolled preliminary study. |
2016-10-11 |
2023-08-13 |
Not clear |
| Antonio Bruno, Gianluca Pandolfo, Clemente Cedro, Giuseppa Gallo, Mariangela De Felice, Rocco A Zoccali, Maria Rosaria A Muscatell. Effect of Ziprasidone Augmentation of Serotonin Reuptake Inhibitors in Treatment-Resistant Obsessive-Compulsive Disorder: A 12-Week, Open-Label Uncontrolled Preliminary Study. Clinical neuropharmacology. vol 39. issue 1. 2016-10-11. PMID:26757309. |
the present 12-week, open-label uncontrolled trial was aimed to explore the efficacy of ziprasidone add-on pharmacotherapy on clinical symptoms and cognitive functioning in a sample of patients with treatment-resistant obsessive-compulsive disorder receiving serotonin reuptake inhibitors (sris). |
2016-10-11 |
2023-08-13 |
Not clear |
| Christine Lochner, Samuel R Chamberlain, Martin Kidd, Naomi A Fineberg, Dan J Stei. Altered cognitive response to serotonin challenge as a candidate endophenotype for obsessive-compulsive disorder. Psychopharmacology. vol 233. issue 5. 2016-09-30. PMID:26645225. |
altered cognitive response to serotonin challenge as a candidate endophenotype for obsessive-compulsive disorder. |
2016-09-30 |
2023-08-13 |
Not clear |
| Louise Smith, Derek K Tracy, Giovanni Giarol. What Future Role Might N-Acetyl-Cysteine Have in the Treatment of Obsessive Compulsive and Grooming Disorders?: A Systematic Review. Journal of clinical psychopharmacology. vol 36. issue 1. 2016-09-26. PMID:26629962. |
licensed pharmacological treatments for obsessive-compulsive disorders include selective serotonin reuptake inhibitors and tricyclic antidepressants. |
2016-09-26 |
2023-08-13 |
Not clear |
| E Kim, O D Howes, J W Park, S N Kim, S A Shin, B-H Kim, F E Turkheimer, Y-S Lee, J S Kwo. Altered serotonin transporter binding potential in patients with obsessive-compulsive disorder under escitalopram treatment: [11C]DASB PET study. Psychological medicine. vol 46. issue 2. 2016-09-19. PMID:26423910. |
altered serotonin transporter binding potential in patients with obsessive-compulsive disorder under escitalopram treatment: [11c]dasb pet study. |
2016-09-19 |
2023-08-13 |
Not clear |
| Russell J Lewis, Philip M Kemp, Robert D Johnso. Paroxetine in Postmortem Fluids and Tissues from Nine Aviation Accident Victims. Journal of analytical toxicology. vol 39. issue 8. 2016-09-09. PMID:26378138. |
paroxetine is a selective serotonin reuptake inhibitor commonly prescribed for the treatment of depression, obsessive-compulsive disorder, panic disorder, social anxiety disorder and post-traumatic stress disorder. |
2016-09-09 |
2023-08-13 |
Not clear |
| Mehdi Sayyah, Kaveh Eslami, Shabnam AlaiShehni, Leila Kout. Cognitive Function before and during Treatment with Selective Serotonin Reuptake Inhibitors in Patients with Depression or Obsessive-Compulsive Disorder. Psychiatry journal. vol 2016. 2016-09-06. PMID:27597949. |
cognitive function before and during treatment with selective serotonin reuptake inhibitors in patients with depression or obsessive-compulsive disorder. |
2016-09-06 |
2023-08-13 |
Not clear |